345 related articles for article (PubMed ID: 12052096)
1. Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.
Ginsberg G; Lowe S
Pharmacoeconomics; 2002; 20(6):367-87. PubMed ID: 12052096
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.
Ackerman SJ; Sullivan EM; Beusterien KM; Natter HM; Gelinas DF; Patrick DL
Pharmacoeconomics; 1999 Feb; 15(2):179-95. PubMed ID: 10351191
[TBL] [Abstract][Full Text] [Related]
3. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.
Tavakoli M; Malek M
J Neurol Sci; 2001 Oct; 191(1-2):95-102. PubMed ID: 11676998
[TBL] [Abstract][Full Text] [Related]
4. A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.
Thakore NJ; Pioro EP; Udeh BL; Lapin BR; Katzan IL
Value Health; 2020 Dec; 23(12):1543-1551. PubMed ID: 33248509
[TBL] [Abstract][Full Text] [Related]
5. ALS/MND and the perspective of health economics.
Gray AM
J Neurol Sci; 1998 Oct; 160 Suppl 1():S2-5. PubMed ID: 9851642
[TBL] [Abstract][Full Text] [Related]
6. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
[TBL] [Abstract][Full Text] [Related]
7. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
8. A fair innings for NICE?
Freemantle N; Bloor K; Eastaugh J
Pharmacoeconomics; 2002; 20(6):389-91. PubMed ID: 12052097
[No Abstract] [Full Text] [Related]
9. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Moore DH
Cochrane Database Syst Rev; 2000; (2):CD001447. PubMed ID: 10796796
[TBL] [Abstract][Full Text] [Related]
10. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Moore DH
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD001447. PubMed ID: 22419278
[TBL] [Abstract][Full Text] [Related]
11. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460
[TBL] [Abstract][Full Text] [Related]
12. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Moore DH
Cochrane Database Syst Rev; 2001; (4):CD001447. PubMed ID: 11687111
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.
Messori A; Trippoli S; Becagli P; Zaccara G
Pharmacoeconomics; 1999 Aug; 16(2):153-63. PubMed ID: 10539396
[TBL] [Abstract][Full Text] [Related]
14. Riluzole for the treatment of amyotrophic lateral sclerosis.
Saitoh Y; Takahashi Y
Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness associated with amyotrophic lateral sclerosis: some questions and answers pending.
Fiorentino G; Esquinas AM
Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):315-316. PubMed ID: 29191046
[No Abstract] [Full Text] [Related]
16. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy.
Georgoulopoulou E; Fini N; Vinceti M; Monelli M; Vacondio P; Bianconi G; Sola P; Nichelli P; Mandrioli J
Amyotroph Lateral Scler Frontotemporal Degener; 2013 Sep; 14(5-6):338-45. PubMed ID: 23373475
[TBL] [Abstract][Full Text] [Related]
17. Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis.
Hodgkinson VL; Lounsberry J; Mirian A; Genge A; Benstead T; Briemberg H; Grant I; Hader W; Johnston WS; Kalra S; Linassi G; Massie R; Melanson M; O'Connell C; Schellenberg K; Shoesmith C; Taylor S; Worley S; Zinman L; Korngut L
Can J Neurol Sci; 2018 Nov; 45(6):652-659. PubMed ID: 30430962
[TBL] [Abstract][Full Text] [Related]
18. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole.
Riviere M; Meininger V; Zeisser P; Munsat T
Arch Neurol; 1998 Apr; 55(4):526-8. PubMed ID: 9561981
[TBL] [Abstract][Full Text] [Related]
19. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
Bellingham MC
CNS Neurosci Ther; 2011 Feb; 17(1):4-31. PubMed ID: 20236142
[TBL] [Abstract][Full Text] [Related]
20. Improvements in the multidisciplinary care are beneficial for survival in amyotrophic lateral sclerosis (ALS): experience from a tertiary ALS center.
Klavžar P; Koritnik B; Leonardis L; Dolenc Grošelj L; Kirbiš M; Ristić Kovačič S; Klinar P; Pohar Perme M; Zidar J
Amyotroph Lateral Scler Frontotemporal Degener; 2020 May; 21(3-4):203-208. PubMed ID: 32248716
[No Abstract] [Full Text] [Related]
[Next] [New Search]
